Comparative Study on the Pharmacokinetic Profiles of Three Bioactive Components from Buxue Yimu Pills in Aborted Rats with Blood Stasis Versus Normal Rats Using UPLC-TSG-FORTIS Mass Spectrum

Anqi Wang,Lin Li,Shan Zeng,Di Wang,Wei Li,Yi Liu,Mengyao Wu,Liang Zou,Peng Zhang,Yun Gong,Yan Zhang
DOI: https://doi.org/10.2139/ssrn.4177878
2022-01-01
Abstract:Buxue Yimu pills, one of the well-known traditional Chinese herbal preparations, are usually prescribed for the treatment of qi and blood deficiency and blood stasis syndromes, as well as for the treatment of postpartum abdominal pain syndromes. To present, the pharmacokinetic behaviors of the bioactive compounds from this preparation in vivo still have not been systematically reported. In this study, the pharmacokinetic behaviors of three bioactive components from Buxue Yimu pills, including Leonurine, Formononetin and Ligustilide, are simultaneously investigated in aborted rats with blood stasis and normal rats using UPLC-TSQ-FORTIS mass spectrum. Plasma samples were prepared by protein precipitation with acetonitrile and methanol and separated by an Accucore C18 ColumnSet analytical column (100*2.1mm, 2.6 μm) equipped with a gradient elution system containing acetonitrile-water (0.1% formic acid) at a flow-rate of 0.2 mL/min. Components were then detected by a mass spectrometer in electrospray ionization mode conducted by multi reaction monitoring scanning under both positive mode. This method showed good linearity, precision, accuracy, recovery, stability, and negligible matrix effects, which were within acceptable ranges. The method was successfully applied to compare the pharmacokinetics in aborted rats with blood stasis and normal rats treated with Buxue Yimu pills. Significant differences ( p < 0.05) were found in the Cmax for Leonurine ( 27.25 ± 7.52 vs 18.48 ± 5.61 ) and Ligustilide ( 815.36±151.49 vs 537.05 ± 198.57 ), and Cl_F_obs for Leonurine ( 123.72 ± 20.74 vs 138.35 ± 63.92 ) between aborted rats with blood stasis and normal groups. This result implied that the pharmacokinetic profiles of these three bioactive components from this preparation in normal and model rats were not significant different. It is suggested the dosage of Buxue Yimu Pills for clinical treatment might not be changed based on the results.
What problem does this paper attempt to address?